ELI LILLY & Co (LLY) operating KPIs
LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3026% above fair value
$1417.54+43.84 (+3.19%)
Close on Oct 30, 2026Market cap $1.33TP/E 46.0Yield 0.44%
Eli Lilly strattera (atomoxetine) — Worldwide revenue YoY (%) [legacy] (%)
Quarterly figures from Eli Lilly's filings and investor materials
Latest, Q3 2019
-47.0%
Period ended Sep 30, 2019
Change on a year earlier
-19.0 pts
-28.0% in Q3 2018
History
6 quarters
Since Q1 2018
Sources
6
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Strattera (atomoxetine) — Worldwide revenue YoY (%) [legacy] (%) | Year on year | Source |
|---|---|---|---|---|
| Q3 2019 | Sep 30, 2019 | -47.0% | -19.0 pts | Form 10-Q FY2019Q3 (filed 2019-10-25) ↗ |
| Q2 2019 | Jun 30, 2019 | -28.0% | +11.0 pts | Form 10-Q FY2019Q2 (filed 2019-08-02) ↗ |
| Q1 2019 | Mar 31, 2019 | -49.0% | -16.0 pts | Form 10-Q FY2019Q1 (filed 2019-05-02) ↗ |
| Q3 2018 | Sep 30, 2018 | -28.0% | – | Form 10-Q FY2018Q3 (filed 2018-11-06) ↗ |
| Q2 2018 | Jun 30, 2018 | -39.0% | – | Form 10-Q FY2018Q2 (filed 2018-07-25) ↗ |
| Q1 2018 | Mar 31, 2018 | -33.0% | – | Form 10-Q FY2018Q1 (filed 2018-04-27) ↗ |
Cite this data
StockData. (2026). Eli Lilly Strattera (atomoxetine) — Worldwide revenue YoY (%) [legacy] (%), quarterly Q1 2018–Q3 2019 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/med_strattera_yoy
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.